Elevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndrome

Experimental and Molecular Pathology

Volumn 96, Issue 3, 2014, Pages 422-425

  Fourie, Nicolaas H ^a   Peace, Ralph Michael ^a,b   Abey, Sarah K ^a   Sherwin, LeeAnne B ^a   Rahim Williams, Bridgett ^a,c   Smyser, Paul A ^a   Wiley, John W ^d   Henderson, Wendy A ^a  

^a NATIONAL INSTITUTE OF NURSING RESEARCH   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Hsa miR 342 3p; Hsa miRNA 150; Irritable bowel syndrome; MicroRNA

Indexed keywords

MICRORNA; MICRORNA 150; MICRORNA 342 3P; PROTEIN KINASE B BETA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COLON MOTILITY; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; IRRITABLE COLON; MALE; MOLECULAR PATHOLOGY; MUSCLE FUNCTION; PAIN; PILOT STUDY; RACISM; RNA ANALYSIS; SEX DIFFERENCE;

HSA-MIR-342-3P; HSA-MIRNA-150; IRRITABLE BOWEL SYNDROME; MICRORNA;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENETIC MARKERS; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; UP-REGULATION; YOUNG ADULT;

EID: 84899791279     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2014.04.009     Document Type: Article

References (20)

1. Anderson E.C., Wong M.H. Caught in the Akt: regulation of Wnt signaling in the intestine. Gastroenterology 2010, 139:718-722.
2. Ashburn T.T., Gupta M.S. The IBS market. Nat. Rev. Drug Discov. 2006, 5:99-100.
3. Chadwick V.S., et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002, 122:1778-83.
4. Demaude J., et al. Phenotypic changes in colonocytes following acute stress or activation of mast cells in mice: implications for delayed epithelial barrier dysfunction. Gut 2006, 55:655-661.
5. Drossman D.A. Introduction. The Rome Foundation and Rome III. Neurogastroenterol. Motil. 2007, 19:783-786.
6. Gheinani A.H., et al. Deciphering microRNA code in pain and inflammation: lessons from bladder pain syndrome. Cell. Mol. Life Sci. 2013, 70:3773-3789.
7. Henderson W.A., et al. Inverse relationship of interleukin-6 and mast cells in children with inflammatory and non-inflammatory abdominal pain phenotypes. World J. Gastrointest. Pathophysiol. 2012, 3:102-108.
8. Kapeller J., et al. First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum. Mol. Genet. 2008, 17:2967-2977.
9. Kerckhoffs A.P., et al. SERT and TPH-1 mRNA expression are reduced in irritable bowel syndrome patients regardless of visceral sensitivity state in large intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302:G1053-G1060.
10. Lipscombe D., et al. Alternative splicing: functional diversity among voltage-gated calcium channels and behavioral consequences. Biochim. Biophys. Acta 2013, 1828:1522-1529.
11. Ma Y., et al. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut 2012, 61:1447-1453.
12. Miwa J., et al. Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits. Digestion 2001, 63:188-194.
13. Orlova I.A., et al. MicroRNA modulation in complex regional pain syndrome. J. Transl. Med. 2011, 9:195-205.
14. Peace R.M., et al. Circulating miRNAs in IBS. Clin. Trans. Sci. 2012, 5:181.
15. Pekow J.R., Kwon J.H. MicroRNAs in inflammatory bowel disease. Inflamm. Bowel Dis. 2012, 18:187-193.
16. Piche T., et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009, 58:196-201.
17. Vivinus-Nébot M., et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut. 2014, 63:744-752.
18. Zhang M., et al. Increased colonic motility in a rat model of irritable bowel syndrome is associated with up-regulation of L-type calcium channels in colonic smooth muscle cells. Neurogastroenterol. Motil. 2010, 22:e162-e170.
19. Zhou Q., Verne G.N. miRNA-based therapies for the irritable bowel syndrome. Expert. Opin. Biol. Ther. 2011, 11:991-995.
20. Zhou Q., et al. MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. Gut 2010, 59:775-784.